Methylphenidate: Difference between revisions
From Pharmacopedia
More actions
| [checked revision] | [checked revision] |
MDElliottMD (talk | contribs) Pharmacopedia: remove contraindications parameter |
MDElliottMD (talk | contribs) Pharmacopedia: add <pharmaInteractions/> |
||
| Line 59: | Line 59: | ||
Notably, '''few CYP-mediated interactions''' because methylphenidate is metabolized by CES1, not P450s — a clinical advantage over amphetamine when polypharmacy is a concern. | Notably, '''few CYP-mediated interactions''' because methylphenidate is metabolized by CES1, not P450s — a clinical advantage over amphetamine when polypharmacy is a concern. | ||
<pharmaInteractions/> | |||
| pregnancy_details = Category C. Crosses the placenta. Less reproductive data than amphetamine; available evidence does not show a clear pattern of major teratogenicity, but cohort studies suggest small increases in cardiac malformations and other anomalies — interpretation complicated by confounding by indication. Third-trimester exposure can produce transient neonatal withdrawal (irritability, feeding difficulty). Generally a risk-benefit decision; many patients defer ADHD treatment during pregnancy. Excreted in breast milk in small amounts; breastfeeding generally compatible at therapeutic doses with infant monitoring. | | pregnancy_details = Category C. Crosses the placenta. Less reproductive data than amphetamine; available evidence does not show a clear pattern of major teratogenicity, but cohort studies suggest small increases in cardiac malformations and other anomalies — interpretation complicated by confounding by indication. Third-trimester exposure can produce transient neonatal withdrawal (irritability, feeding difficulty). Generally a risk-benefit decision; many patients defer ADHD treatment during pregnancy. Excreted in breast milk in small amounts; breastfeeding generally compatible at therapeutic doses with infant monitoring. | ||
| monitoring = * Baseline: cardiovascular history (including family history of sudden cardiac death), blood pressure, heart rate, weight/height, mental health history, history of tics or substance use | | monitoring = * Baseline: cardiovascular history (including family history of sudden cardiac death), blood pressure, heart rate, weight/height, mental health history, history of tics or substance use | ||